Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

ISOSORBIDE-5-MONONITRATE

All strengths: Off-Formulary Interchangeable, not an ODB benefit; same patient cost rules

Shared coverage and patient cost rules
StatusOff-Formulary Interchangeable, not an ODB benefit
Patient paysPatient pays: program not supplied; amount cannot be determined.

Other products in the same Health Canada class (C01D, C01DA) — coverage varies; not interchangeable

  • Isosorbide dinitrate (Isdn): general benefit, Not a benefit
  • Nitroglycerin (Transderm-Nitro): general benefit, Not a benefit, Listing status unconfirmed
  • Vericiguat (Verquvo): limited Use 685

Apo-ISMN · DIN 02272830 · 60mg · extended release tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-ISMN · DIN 02272830 Manufacturer: Apotex Inc.; listing date 2008-06-27 Health Canada: Marketed since 2006-03-03 · brand APO-ISMN · ATC C01DA14 ISOSORBIDE MONONITRATE · form Tablet (extended-release) · route Oral · ingredients ISOSORBIDE-5-MONONITRATE 60 MG · company Apotex inc · schedule Ethical
Check this DIN again · Health Canada product record

Apo-ISMN: Formulary list price $0.4950/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4950 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75834 · Verify on the e-Formulary ↗ (DIN 02272830)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02272830). DIN 02272830: Apo-ISMN Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 241200088; group id 367; item number 0858; lccId None; manufacturer id APX Source form: ER Tab; strength: 60mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $0.4950; ministry $0.4950 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02272830 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75834
Interchangeable products
Imdur · DIN 02126559 · not recorded PMS-ISMN · DIN 02301288 · $0.4950
Shortage status: resolved shortage (ended 2025-05-29); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02272830
Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMS-ISMN · DIN 02301288 · 60mg · extended release tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
PMS-ISMN · DIN 02301288 Manufacturer: Pharmascience Inc.; listing date 2008-08-28 Health Canada: Marketed since 2007-11-08 · brand PMS-ISMN · ATC C01DA14 ISOSORBIDE MONONITRATE · form Tablet (extended-release) · route Oral · ingredients ISOSORBIDE-5-MONONITRATE 60 MG · company Pharmascience inc · schedule Ethical
Check this DIN again · Health Canada product record

PMS-ISMN: Formulary list price $0.4950/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4950 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78661 · Verify on the e-Formulary ↗ (DIN 02301288)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02301288). DIN 02301288: PMS-ISMN Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 241200088; group id 367; item number 0858; lccId None; manufacturer id PMS Source form: ER Tab; strength: 60mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $0.4950; ministry $0.4950 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02301288 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78661
Interchangeable products
Apo-ISMN · DIN 02272830 · $0.4950 Imdur · DIN 02126559 · not recorded
Shortage status: discontinued (2026-09-03, reported by PHARMASCIENCE INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02301288
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Imdur · DIN 02126559 · 60mg · extended release tablet

Off-Formulary Interchangeable, not an ODB benefitDormant since 2026-07-29 · checked 2026-09-02 · What does dormant mean?
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Imdur · DIN 02126559 Manufacturer: AstraZeneca; listing date 2008-06-27 Health Canada: Dormant since 2026-07-29 · brand IMDUR · ATC C01DA14 ISOSORBIDE MONONITRATE · form Tablet (extended-release) · route Oral · ingredients ISOSORBIDE-5-MONONITRATE 60 MG · company Juno pharmaceuticals corp. · schedule Ethical
Check this DIN again · Health Canada product record

Imdur: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=16804 · Verify on the e-Formulary ↗ (DIN 02126559)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02126559). DIN 02126559: Imdur Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 241200088; group id 367; item number 0858; lccId None; manufacturer id AZC Source form: ER Tab; strength: 60mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02126559 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=16804
Interchangeable products
Apo-ISMN · DIN 02272830 · $0.4950 PMS-ISMN · DIN 02301288 · $0.4950
Shortage status: discontinued (2024-10-28, reported by JUNO PHARMACEUTICALS CORP.); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02126559
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2026-07-29 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (24:12 Vasodilating Drugs) and how they are covered

Matched class: 24:12 Vasodilating Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Some products covered without a code (check the product listing): ISOSORBIDE DINITRATE, NITROGLYCERIN 24:12 Vasodilating Drugs

ISOSORBIDE DINITRATE

· 6 products · General benefit (3), Listed, not a benefit (3) · strengths: 5mg, 10mg, 30mg · SL Tab, Tab

NITROGLYCERIN

· 20 products · General benefit (13), Temporary benefit (2), Listed, not a benefit (1), Off-Formulary Interchangeable, not an ODB benefit (4) · strengths: 0.4mg/Hr/20 Sq Cm, 0.6mg/Hr/30 Sq Cm, 0.4mg/Hr/14 Sq Cm, 0.6mg/Hr/21 Sq Cm, 0.3mg, 0.6mg, 0.4mg/Metered Dose, 0.2mg/Hr, 0.4mg/Hr, 0.6mg/Hr, 0.8mg/Hr · Patch, SL Tab, Sp-180 Dose Pk, Sp-75 Dose Pk, Spray-200 Dose Pk, Transdermal Patch

VERICIGUAT

· 3 products · Limited Use, codes 685 · strengths: 2.5mg, 5mg, 10mg · Tab

DIPYRIDAMOLE & ACETYLSALICYLIC ACID

· 2 products · Listed, not a benefit (1), Limited Use, codes 349 (1) · strengths: 200mg/25mg · Cap

NIMODIPINE

· 1 products · Limited Use, codes 42, 43 · strengths: 30mg · Tab

AMBRISENTAN

· 7 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 5mg, 10mg · Tab

BETAHISTINE DIHYDROCHLORIDE

· 24 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 8mg, 16mg, 24mg · Tab

BOSENTAN MONOHYDRATE

· 14 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 62.5mg, 125mg · Tab

DIPYRIDAMOLE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 25mg, 50mg, 75mg · Tab

RIOCIGUAT

· 10 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 0.5mg, 1.5mg, 1mg, 2.5mg, 2mg · Tab

TADALAFIL

· 73 products · Off-Formulary Interchangeable, not an ODB benefit (72), Off-Formulary Interchangeable, not an ODB benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1) · strengths: 2.5mg, 5mg, 10mg, 20mg · Tab

VARDENAFIL HCL

· 16 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 10mg, 5mg, 20mg · Orally Disintergrating Tab, Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:12
Full class listing Related classes: 24:04 Cardiac Drugs, 24:06 Antilipemic Drugs, 24:08 Hypotensive Drugs (For Diuretics See 40:28), 24:32 Renin-Angiotensin Aldosterone Inhibitors Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE APO-ISMN (isosorbide-5-mononitrate) is indicated for the prevention of anginal attacks in patients with chronic stable angina pectoris associated with coronary artery disease. APO-ISMN is not intended for the immediate relief of acute attacks of angina pectoris. https://pdf.hres.ca/dpd_pm/00012129.PDF PM date: December 15, 2010 Source product: APO-ISMN; DIN 02272830; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

PMS-ISMN · DIN 02301288 Shortage status: discontinued (2026-09-03, reported by PHARMASCIENCE INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02301288

Check this DIN again

Imdur · DIN 02126559 Shortage status: discontinued (2024-10-28, reported by JUNO PHARMACEUTICALS CORP.); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02126559

Check this DIN again
Health Canada: dormant products
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, Sep 10, 2026 ↗)

Other review policies

For Apo-ISMN, PMS-ISMN, Imdur: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026